top of page

Abecma

Multiple Myeloma Abecma


Abecma is a CAR T-cell therapy used for treating multiple myeloma, a type of blood cancer. It involves using a patient's own T cells, which are collected and genetically modified to target the BCMA (B-cell maturation antigen) protein found on myeloma cells. Once reintroduced into the patient's body, these engineered T cells can recognize and kill the cancer cells.

Abecma is typically used in patients who have already undergone at least four prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. It has shown significant efficacy in treating patients with relapsed or refractory multiple myeloma, providing a new option for those who have not responded well to other treatments.

bottom of page